Filing Details
- Accession Number:
- 0000899243-16-013610
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-17 18:47:20
- Reporting Period:
- 2016-02-17
- Filing Date:
- 2016-02-17
- Accepted Time:
- 2016-02-17 18:47:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1445283 | Proteostasis Therapeutics Inc. | PTI | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1114448 | Ag Novartis | Lichtstrasse 35 Basel V8 4056 | No | No | Yes | No | |
1297709 | Ltd Bioventures Novartis | 131 Front Street Hamilton D0 HM12 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-02-17 | 1,498,791 | $0.00 | 1,498,791 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2016-02-17 | 375,000 | $8.00 | 1,873,791 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Convertible Redeemable Preferred Stock | Disposition | 2016-02-17 | 10,000,000 | $0.00 | 1,318,932 | $0.00 |
Common Stock | Series B Convertible Redeemable Preferred Stock | Disposition | 2016-02-17 | 1,944,315 | $0.00 | 179,859 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct |
Footnotes
- This transaction represents the total number of shares of Common Stock of the Issuer (the "Issuer Common Stock") received upon the conversion of the Issuer's Series A Convertible Redeemable Preferred Stock (the "Series A Shares"), the payment of accrued dividends on the Series A Shares and the conversion of the Issuer's Series B Convertible Redeemable Preferred Stock (the "Series B Shares", collectively, the "Preferred Shares").
- These securities are held directly by Novartis Bioventures Ltd. ("Novartis Bioventures"). Novartis Bioventures is a corporation organized under the laws of Bermuda and is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG is a corporation organized under the laws of Switzerland and is the publicly owned parent of Novartis Bioventures Ltd.
- These securities were purchased in connection with the initial public offering of the Issuer.
- The Preferred Shares automatically converted into Issuer Common Stock on a 10.8102-to-1 basis upon the closing of the initial public offering of the Issuer without payment or further consideration. The Preferred Shares were convertible at any time at the election of the Reporting Person and had no expiration date.
- These securities include shares of Issuer Common Stock received as payment for accrued dividends on the Series A Shares.